Use of IAP inhibitor and oncolytic virus in preparation of anti-tumor drug
US10980850B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2017 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Aug 18, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.